“On behalf of the MediGene Supervisory Board, I would like to thank Dr Peter Heinrich for his long time and successful leadership as Chief Executive Officer of the company. As a co-founder, he essentially shaped the company from the beginning. Due to his entrepreneurial achievements, MediGene today is an internationally acknowledged biotech company with subsidiaries in the UK and the USA and is listed in the German stock index TecDAX. The supervisory Board expresses its heartfelt thankfulness for his achievements and wishes him all the best for his future path of life”, says Dr Ernst-Ludwig Winnacker, chairman of the supervisory board of MediGene.

Dr. Mathias studied pharmacy at Paris VI University, taking his PhD in 1991. He embarked on his career in industry in 1988 as International Product Manager with Hoechst AG, Frankfurt, then in 1990 joined Albert-Roussel Pharma GmbH in Wiesbaden, first as a pharmaceuticals officer, then as a product group manager and as deputy head of marketing. In 1995 Dr. Mathias launched the Anti-Infectives Marketing Department at Hoechst Pharma in Frankfurt before moving as head of marketing to Servier Deutschland GmbH in Munich and taking over as general manager there in 1996. In 2002 he moved as head of marketing to Amgen GmbH, Munich, the company he led successfully as general manager since 2003. In April 2008, he joined the executive board of MediGene.

“I would like to express my thanks for the trust put in me by to the Supervisory Board. I accept the new challenge with great pleasure and a deep confidence that MediGene AG will continue to develop successfully. MediGene has an excellent team of employees and I look very much forward to working with them furthermore”, says Dr Frank Mathias, the new chief executive officer of MediGene.